Modelling cost effectiveness of horse antithymocyte globulin for treating severe aplastic anaemia in Germany

Heublein, Steffen; Wehner, Franziska; Höchsmann, Britta; Hochhaus, Andreas; Hartmann, Michael; Rosée, Paul La

doi:10.1007/s00277-013-1688-2

Cited by 7 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further analysis showed that when the medical insurance reimbursement ratio was 0, the QALY gained by patients with CsA + ALG was about 687,000 yuan, while the QALY gained by patients with CsA + TPO-RA was about 450,000 yuan. Even if the reimbursement rate of medical insurance reaches 70%, the cost of each QALY obtained by the two regimens is more than 200,000 yuan, comparable to the world [30]. Compared with the CsA + TPO-RA scheme, the total cost of each additional QALY using the CsA + ALG scheme was 1.51 million yuan, but this far exceeded the cost-utility threshold for each QALY obtained in China [24].…”

Section: Study Summarymentioning

confidence: 99%

Cost-utility Analysis of Adult Patients with Severe Aplastic Anemia: a Single-center Cohort Study

Chen,

Fang,

Kuang

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: This study aimed to evaluate the efficacy of cyclosporine A + ALG and cyclosporine A + TPO-RA in treating SAA (Severe Aplastic Anemia) patients and provide scientific data support for maximizing the therapeutic benefit of SAA patients. Methods: Cost-utility analysis was used to compare the two strategies' quality-adjusted years of life and total costs. Patient utility values were obtained by EQ-5D-3L and Japanese TTO conversion, and total treatment costs were obtained by electronic questionnaire and medical information data. Results: Twenty-six adult patients were enrolled, including 17 patients in the cyclosporine A + ALG group and nine in the cyclosporine A + TPO-RA group. From admission to 6 months follow-up, the intuitive feelings of patients in the cyclosporine A + ALG group were higher than of those in the cyclosporine A + TPO-RA group, and the quality of life of the former group was significantly higher than that of the latter, with a difference of 0. 08 QALY (P < 0.01). The total cost of the former was twice that of the latter. The QALYs obtained by the two strategies were 687,000 yuan and 450,000 yuan, respectively. Compared with the cyclosporine A + TPO-RA regimen, the total cost of the cyclosporine A + ALG regimen was 1.51 million yuan per additional QALY. Conclusions: Under the premise of ensuring clinical efficacy, CsA + TPO-RA can be used as a better treatment strategy to reduce the economic pressure of SAA patients, reduce the pressure of medical insurance, and obtain multi-benefits.

show abstract

Section: Study Summarymentioning

confidence: 99%

Cost-utility Analysis of Adult Patients with Severe Aplastic Anemia: a Single-center Cohort Study

Chen,

Fang,

Kuang

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Further analysis shows that when the medical insurance reimbursement ratio is 0, the QALY obtained by patients with CsA + ALG scheme is about 687,000 yuan, while that obtained by patients with CsA + TPO-RA scheme is 450,000 yuan. Even if the medical insurance reimbursement ratio reaches 70%, the cost of each QALY obtained by the two schemes is more than 200,000 yuan, which is equal to that in the world [30]; compared with the CsA + TPO-RA scheme, the total cost of using the CsA + ALG scheme is 1.51 million yuan using each additional QALY, but this is far more than the cost utility threshold for each QALY obtained in China [24].…”

Section: Cur and Icur Of Patients In The Two Treatment Groupsmentioning

confidence: 99%

Cost utility Analysis of Adult Patients with Severe Aplastic Anemia Based on Single-center Study

chen,

fang,

kuang

et al. 2023

Preprint

View full text Add to dashboard Cite

Objective The purpose of this study is to objectively evaluate the efficacy of cyclosporine A + ALG and cyclosporine A + TPO-RA in the treatment of SAA patients, and to provide scientific data support for maximizing the therapeutic benefit of SAA patients. Method Cost-utility analysis was used to compare the quality of life adjusted years and total cost of the two schemes. The patient utility value was obtained from EQ-5D-3L and Japanese TTO conversion, and the total cost of treatment was obtained from electronic questionnaire survey and medical information data. Results A total of 26 adult patients were included in the study, including 17 with cyclosporine A + ALG and 9 with cyclosporine A + TPO-RA. In terms of QALY, patients with cyclosporine A + ALG regimen had higher intuitive feelings than those with cyclosporine A + TPO-RA regimen from admission to 6 months of follow-up, and the quality of life of patients with the former regimen was also significantly higher than that of the latter, with a difference of 0. 08 QALY (P < 0.01). In terms of total cost, the total cost of the former was twice that of the latter. Each QALY obtained by the two regimens was 687,000 yuan and 450,000 yuan, respectively. Compared with the cyclosporine A + TPO-RA regimen, the total cost of each QALY increased by the cyclosporine A + ALG regimen was 1.51 million yuan. Conclusion On the premise of ensuring the effectiveness of diagnosis and treatment, CsA + TPO-RA can be used as a good treatment option, which can reduce the economic pressure of SAA patients, reduce the burden of disease, reduce the pressure of medical insurance funds, and achieve multi-benefits.

show abstract

“…A summary of studies is presented in Table 1. [6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23] Diseases Seven studies evaluated therapy for β-thalassaemia, one for AIHA, one for chemotherapy-induced anaemia, one for chronic heart failure-related anaemia, two for SAA, and six for CKD-related anaemia.…”

Section: Overviewmentioning

confidence: 99%

Economic Evaluation of Severe Anaemia: Review-Based Recommendations and a Conceptual Framework

2020

EMJ

View full text Add to dashboard Cite

Objective: Novel anaemia treatments have greatly improved patient outcomes in the last decade and have also undergone economic evaluations in various settings using heterogenous model structures, costs, and inputs. The objectives were to review published economic evaluation studies in major red blood cell disorders, identify limitations in the applied methodology, provide a set of recommendations, and produce a conceptual framework for future economic research in this disease area. Methods: A targeted search was conducted for economic literature evaluating treatments in major red blood cell disorders related to anaemia. Disorders included autoimmune haemolytic anaemia, β-thalassaemia, chemotherapy-induced anaemia, anaemia in chronic kidney disease, and severe aplastic anaemia. Budget impact models and cost-effectiveness and cost-utility analyses were considered. Modelling assumptions regarding the model structure, time horizon, perspective, and type of costs were reviewed and recommendations and a conceptual framework for future economic analyses were created. Results: A total of four budget impact models, nine cost-utility analyses, and four cost-effectiveness analyses were investigated. A major limitation was that the included costs varied significantly across studies. Costs which were rarely included, and generally should be considered, were related to adverse events, mortality, and productivity. Additionally, relationships between levels of serum ferritin, hepatic or total body iron, and haemoglobin with long-term complications and mortality were rarely included. Conclusion: Published economic analyses evaluating treatments for major red blood cell disorders frequently exclude vital costs. A set of recommendations and a conceptual framework will aid researchers in applying a more comprehensive approach for economic evaluations in major red blood cell disorders.

show abstract

Modelling cost effectiveness of horse antithymocyte globulin for treating severe aplastic anaemia in Germany

Cited by 7 publications

References 16 publications

Cost-utility Analysis of Adult Patients with Severe Aplastic Anemia: a Single-center Cohort Study

Cost-utility Analysis of Adult Patients with Severe Aplastic Anemia: a Single-center Cohort Study

Cost utility Analysis of Adult Patients with Severe Aplastic Anemia Based on Single-center Study

Economic Evaluation of Severe Anaemia: Review-Based Recommendations and a Conceptual Framework

Contact Info

Product

Resources

About